Time-trends and treatment gaps in the antithrombotic management of patients with atrial fibrillation after percutaneous coronary intervention: Insights from the CHUM AF-STENT Registry. by Boivin-Proulx, L-A et al.
QUA L I T Y AND OU T COME S
Time-trends and treatment gaps in the antithrombotic
management of patients with atrial fibrillation after
percutaneous coronary intervention: Insights from
the CHUM AF-STENT Registry
Laurie-Anne Boivin-Proulx1 | Ariane Deneault-Marchand1 | Alexis Matteau1 |
Samer Mansour1 | François Gobeil1 | John A. Camm2 | Keith A. A. Fox3 |
Brian J. Potter1
1Centre hospitalier de l'Université de Montréal (CHUM) Research Center and Cardiovascular Center, Montreal, Canada
2St. George's University of London, London, UK
3Centre for Cardiovascular Science and Royal Infirmary, Edinburgh, UK
Correspondence
Brian J. Potter, MDCM SM FRCPC, Carrefour
de l'innovation et évaluation en santé (CIÉS),
Centre de recherche du CHUM (CRCHUM),
Cardiology & Interventional Cardiology,
CHUM, Pavillon S, S03-334, 850, rue St-Denis,
Montréal, QC, Canada, H2X 0A9.
Email: brian.potter@umontreal.ca
Abstract
Background: The management of atrial fibrillation and flutter (AF) patients undergo-
ing percutaneous coronary intervention (PCI) has undergone a rapid recent evolution.
In 2016, the Canadian Cardiovascular Society (CCS) published expert recommenda-
tions to help guide clinicians in balancing bleeding and thrombotic risks in these
patients.
Hypothesis: Antithrombotic regimen prescriptions for AF patients undergoing PCI
evolved after the publication of the 2016 CCS AF guidelines.
Methods: A prospective cohort of AF patients undergoing PCI with placement of a
coronary stent from a single tertiary academic center was analyzed for the rec-
ommended antithrombotic regimen at discharge. Prescribing behavior was compared
between three time periods (Cohort A [2010-2011]; Cohort B [2014-2015]; Cohort
C [2017]) using the χ2 test. In addition, antithrombotic management in Cohorts B and
C were compared to guideline-recommended therapy.
Results: A total of 459 patients with AF undergoing PCI were identified. Clinical and
procedural characteristics were similar between cohorts, with the exception of an
increase in drug-eluting stent (DES) use over time (P < .01). Overall, the rate of oral
anticoagulation (OAC) increased over time (P < .01), associated with an increase in
nonvitamin K OAC prescription (P < .01) and a concomitant decrease in vitamin K
antagonist prescription (P < .01). Despite this, the overall rate of anticoagulation
remains below what would be predicted with perfect guideline compliance (75% vs
94%, P < .01).
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Conclusion: There has been a dramatic shift in clinical practice for AF patients requir-
ing PCI, with increases in prescription of OAC even in the context of an increase in
the use of DES. However, room for further practice optimization still exists.
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1 | INTRODUCTION
Contemporary antithrombotic management of patients with either
atrial fibrillation/flutter (AF) or coronary artery disease (CAD) has
largely been well defined in clinical guidelines.1-4 However, up to 30%
of patients with AF also have CAD5 and the optimal management of
AF patients requiring percutaneous coronary intervention (PCI) has,
up until recently, been less clear. While oral anticoagulation (OAC) is
indicated for the prevention of stroke and systemic embolism in most
cases of AF,6 dual antiplatelet therapy (DAPT) is recommended after
PCI in patients without AF.7,8 Simply combining these two recommen-
dations in patients with AF requiring PCI (so-called triple anti-
thrombotic therapy, TATT) increases the bleeding risk significantly.9
In 2016, both the Canadian Cardiovascular Society (CCS) and
European Society of Cardiology (ESC) published expert recommenda-
tions to help guide clinicians in balancing bleeding and thrombotic
risks in these patients.1,3 The landmark PIONEER AF-PCI10 was also
published in 2016, followed closely by REDUAL11 and then
AUGUSTUS,12 providing further evidence in support of nonvitamin K
oral anticoagulation (NOAC)-based antithrombotic regimens that
could minimize the bleeding risk in AF patients having benefitted
from PCI.
A recent international multicenter analysis demonstrated that the
availability of newer antiplatelet and anticoagulant agents was associ-
ated with a significant increase in practice variability in the manage-
ment of AF patients post-PCI, but also that a major shift in clinical
practice would be necessary in order to align with AF guidelines.13
We therefore sought in this analysis to determine whether the publi-
cation of the 2016 CCS and ESC guidelines, in conjunction with land-
mark clinical trials, were associated with such a change in practice
patterns and to assess the size any residual treatment gap.
2 | METHODS
We conducted a single-center retrospective cohort analysis of a pro-
spective registry in accordance with the Strengthening the Reporting
of Observational Studies in Epidemiology guidelines.14 The need for
informed consent was waived by the local institutional research com-
mittee. The study protocol was consistent with the ethical guidelines
of the 1975 Declaration of Helsinki as testified by the approval of the
institution's research committee. All consecutive AF patients
>18 years of age undergoing PCI with coronary stenting at the Centre
hospitalier de l'Université de Montréal during three time periods of
interest were enrolled1: Cohort A, representing a “historic” period
prior to the availability of newer P2Y12-inhbitors and NOACs
(January 2010 to December 2011)2; Cohort B, corresponding to a
“pre-guidelines” period (January 2013 to December 2015) where
novel antithrombotics were clinically available, but evidence-based
guidance for this patient population was lacking; and Cohort C, a
“post-guidelines” period (January to December 2017). Patients with
additional non-AF indications for, or a documented contraindication
to OAC, were excluded from the analysis. Additionally, four patients,
who participated in a clinical trial and for whom the type of anti-
thrombotic therapy could not be determined, were excluded.
The primary outcome of interest was the antithrombotic (anti-
platelet and anticoagulation) regimen recommended at hospital dis-
charge. Data regarding baseline patient characteristics, clinical
presentation, procedural data, and in-hospital outcomes were also
extracted from hospital medical records.
Baseline characteristics of patients and procedural data are pres-
ented both in aggregate and separately for the three cohorts. Contin-
uous data are expressed as mean with SD, and categorical/binary data
are expressed as counts and percent proportions. Baseline compari-
sons between Cohort B and Cohort C were made using a one-way
ANOVA or the Kruskal-Wallis test, as appropriate, for continuous
data, the median test for ordinal data, and the χ2 test for categorical
data. The primary analysis consisted of an evaluation of the difference
in prescription patterns across cohorts using the χ2 test. Secondarily,
we performed an evaluation of the differences between anti-
thrombotic prescription patterns in the pre- (Cohort B) and pos-
tguidelines (Cohort C) cohorts and the patterns that would have been
expected in those cohorts according to the 2016 CCS AF Guidelines.
The expected treatment with perfect guideline adherence was
determined by first assessing the indication for anticoagulation for
each patient by calculating each individual's CHADS2 score and com-
bining it with consideration of the patient's age (≥65 years), as rec-
ommended in the 2016 AF guidelines. Patients with an estimated
glomerular filtration rate (eGFR) ≥30 mL/min (Cockroft-Gault for-
mula)15 and a CCS guidelines indication for OAC would be expected
to receive a NOAC-based regimen, whereas those with eGFR
<30 mL/min would receive VKA, in accordance with monograph rec-
ommendations for most NOACs in Canada at the time (apixaban had
an indication for eGFR as low as 25 mL/min). Patients without a
guideline indication for oral anticoagulant (OAC) were expected to
receive DAPT at discharge. These expected treatments were then
compared to the observed treatments in Cohorts B and C using the
χ2 test.
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TABLE 1 Characteristics and antithrombotic management of AF patients post-PCI
Total cohort Cohort A (2010-2011) Cohort B (2014-2015) Cohort C (2017) P-valuea
Baseline Characteristics N = 459 N = 109 N = 246 N = 104
Age, y ± SD 73.2 ± 9.4 72.3 ± 9.3 73.0 ± 9.5 74.4 ± 9.0 .23
Male sex, n (%) 333 (73%) 81 (74%) 177 (72%) 75 (72%) .89
Diabetes, n (%) 198 (43%) 41 (38%) 104 (42%) 53 (51%) .13
Hypertension n (%) 326 (71%) 68 (62%) 173 (70%) 85 (82%) <.01
Stroke, n (%) 38 (8%) 14 (13%) 17 (7%) 7 (7%) .14
Heart failure, n (%) 116 (25%) 24 (22%) 68 (28%) 24 (23%) .45
Bleeding history, n (%) 16 (3%) 1 (1%) 8 (3%) 7 (7%) .07
Body mass index, kg/m2 ± SD 27.8 ± 6.1 27.5 ± 5.7 28.1 ± 6.3 27.7 ± 6.2 .66
eGFR, mL/min ± SD 69.5 ± 35.8 69.1 ± 38.5 70.5 ± 36.6 67.5 ± 30.7 .77
CHADS2, median (IQR) 2 (1-3) 2 (1-3) 2 (1-3) 2 (1-3) .22
HASBLED, median (IQR) 2 (1-3) 2 (2-3) 2 (2-3) 1 (1-2) <.01
DES use, n (%) 287 (63%) 40 (37%) 150 (61%) 98 (94%) <.01
ACS, n (%) 369 (80%) 98 (90%) 211 (86%) 60 (58%) <.01
Admission medication N = 459 N = 109 N = 246 N = 104
Antiplatelet therapy
ASA, n (%) 307 (67%) 83 (76%) 169 (69%) 55 (53%) <.01
P2Y12, n (%) 48 (11%) 5 (5%) 29 (12%) 14 (13%) .06
Clopidogrel, n (%) 39 (9%) 4 (4%) 23 (9%) 12 (12%) .87b
Prasugrel, n (%) 1 (0%) 1 (1%) 0 (0%) 0 (0%)
Ticagrelor, n (%) 8 (2%) 0 (0%) 6 (2,4%) 3 (2,7%)
Anticoagulation
OAC, n (%) 276 (60%) 50 (46%) 155 (63%) 71 (68%) <.01
VKA, n (%) 135 (30%) 45 (41%) 75 (30%) 15 (14%) <.01
NOAC, n (%) 141 (31%) 5 (5%) 80 (33%) 56 (54%) <.01
In-hospital events N = 459 N = 109 N = 246 N = 104
Major bleeding (BARC 3 or 5) 10 (2%) 1 (1%) 5 (2%) 4 (4%) .28
Death 12 (3%) 5 (5%) 3 (1%) 4 (4%) .13
Discharge medication N = 447 N = 104 N = 243 N = 100
Antiplatelet therapy
ASA, n (%) 436 (98%) 104 (100%) 242 (100%) 90 (90%) <.01
P2Y12, n (%) 441 (99%) 104 (100%) 243 (100%) 94 (94%) <.01
Clopidogrel, n (%) 402 (91%) 104 (100%) 212 (87%) 86 (86%) <.01b
Prasugrel, n (%) 3 (1%) 0 (0%) 2 (1%) 1 (1%)
Ticagrelor, n (%) 36 (8%) 0 (0%) 29 (12%) 7 (7%)
Anticoagulation
OAC, n (%) 193 (43%) 34 (33%) 84 (35%) 75 (75%) <.01
VKA, n (%) 107 (24%) 34 (33%) 61 (25%) 12 (12%) <.01b
NOAC, n (%) 86 (19%) 0 (0%) 23 (9%) 63 (63%)
Combination therapy
DAPT, n (%) 252 (56%) 70 (67%) 159 (65%) 23 (23%) <.01b
TATT, n (%) 181 (40%) 34 (33%) 83 (34%) 64 (64%)
Dual pathway, n (%)b (OAC + P2Y12) 8 (2%) 0 (0%) 1 (0%) 8 (8%)
Abbreviations: ACS, acute coronary syndrome; ASA, acetylsalicylic acid; DAPT, dual antiplatelet therapy; DES, drug-eluting stent; eGFR, estimated glomerular
filtration rate; NOAC, nonvitamin K oral anticoagulant; TATT, triple antithrombotic therapy; OAC, oral anticoagulant; VKA, vitamin K antagonist.
aSignificance applies to difference between Cohorts B and C only.
bP-value for the distribution of OAC or P2Y12-inhibitor type at baseline and on discharge or of the distribution of combination therapy. Novel
P2Y12-inhibitors prasugrel and ticagrelor were grouped together, as were OAC-based regimens, to avoid cells with a zero count.
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All statistical analyses were conducted using SAS 9.3 statistical
software (SAS Institute, Cary, North Carolina). A two-tailed P-value
<.05 was considered statistically significant without correction for
multiple analyses.
3 | RESULTS
A total of 459 patients with AF undergoing PCI were included across
all three cohorts. Clinical and procedural characteristics of patients in
the Cohort A (n = 109), Cohort B (n = 246), and Cohort C (n = 104)
are detailed in Table 1 and were by and large similar between cohorts,
with the exception of an increase in the use of drug-eluted stent
(DES) over time (37% vs 61% vs 94%, P < .01). The in-hospital mortal-
ity rate was 3% overall, and in-hospital major bleeding was 2%
(Table 1).
Antithrombotic prescriptions at both admission and discharge in
each cohort are shown in Table 1. There was a significant increase in
baseline use of OAC between the pre- and postguidelines cohorts
(P < .01) despite a decrease in VKA use (P < .01) due to a marked rise
in NOAC use over time (P < .01). A significant increase in P2Y12
inhibitor use at baseline was also observed (P < .01).
Discharge antithrombotic prescriptions also evolved significantly
over time. The rate of OAC use at discharge was significantly higher
in Cohort C compared to the preguidelines cohorts (P < .01), driven by
a significant increase in use of NOAC (P < .01) at the expense of
postprocedure VKA prescription (P < .01). Consequently, TATT pre-
scription increased significantly (P < .01), whereas DAPT prescription
at discharge was reduced (P < .01). The emergence of a dual pathway
(anticoagulant plus a P2Y12-inhibitor) prescription pattern was also
observed in the most recent (postguidelines) cohort (Cohort C).
“Real-world” and corresponding theoretical CCS guideline-
recommended OAC rates (based on the patient characteristics in each
of Cohorts B and C) are presented in Table 2. Since the publication of
the CCS guidelines in 2016, a clear change in clinical practice was
observed, with a significant increase in the rate of anticoagulation fol-
lowing PCI from 35% to 75% (P < .01) and the rate of NOAC prescrip-
tion at discharge increasing from 23% to 63% (P < .01) after the
publications of the 2016 CCS AF guidelines. Despite this, the overall
rate of anticoagulation (75%) and of NOAC prescription (84% of OAC)
remains below what would be expected with perfect adherence with
the 2016 CCS guidelines in the most recent postguidelines Cohort C
(94% and 91%, respectively; P < .01 for both comparisons).
4 | DISCUSSION
This prospective registry of AF patients undergoing PCI with stent
implantation highlights several findings relevant to clinical practice.
First, the clinical characteristics of AF patients undergoing PCI have
remained stable over time. Despite this, baseline P2Y12-inhibitor and
OAC use have increased and more patients are treated with NOAC at
baseline than before. Discharge prescription of OAC has also signifi-
cantly increased, due to substantial uptake of NOAC therapy, associ-
ated with an increased rate of TATT and dual-pathway antithrombotic
regimens. Also, despite this appropriate increase in intensity of anti-
thrombotic management of AF patients in line with practice guide-
lines, operators at our institution have not avoided the use of DES in
this population; a practice that now closely mirrors the treatment of
non-AF patients. Finally, despite these dramatic shifts in clinical prac-
tice, the overall rate of OAC prescription appears to remain somewhat
below perfect guideline adherence, but clinically appropriate reasons
for this discrepancy may not have been captured by our analysis.
The increased rate of NOAC prescription and a concomitant
decreased VKA prescription reflects the impact of the CCS 2016 AF
guidelines and landmark clinical trials.3,10,11 The higher TATT
TABLE 2 Observed and
guideline-expected rates and type of oral




observed (N = 243)
2016 CCS AF guidelines
“Expected” (N = 243) P-value
Anticoagulation <.01
No 159 (65%) 21 (9%)
Yes 84 (35%) 222 (91%)
Type of anticoagulant <.01
NOAC 23 (27%) 199 (91%)
VKA 61 (73%) 23 (9%)
Postguidelines 2017 Observed
(N = 100)
2016 CCS AF guidelines
“Expected” (N = 100)
P-value
Anticoagulation <.01
No 25 (25%) 6 (6%)
Yes 75 (75%) 94 (94%)
Type of anticoagulant <.01
NOAC 63 (84%) 86 (91%)
VKA 12 (16%) 8 (9%)
Abbreviations: NOAC, nonvitamin K antagonist oral anticoagulant; VKA, vitamin K antagonist.
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prescription rate is in agreement with the CCS 2016 AF guidelines
recommendation of TATT for 3 to 6 months in these patients with
CHADS2 score ≥ 2, placing greater weight on reduction of thrombo-
embolic events and comparatively lesser weight on risk of major
bleeding.3 A course of TATT of a duration of up to 6 months in
patients at high risk of thrombosis was also advocated subsequently
in the 2018 update of the CCS antiplatelet guidelines.16 The emer-
gence of dual pathway antithrombotic therapy (anticoagulant plus a
single antiplatelet agent) in clinical practice, on the other hand, repre-
sents an integration of randomized trial data from PIONEER AF-PCI
(rivaroxaban) and REDUAL (dabigatran) that showed that such a regi-
men could minimize bleeding risk without a signal for increase in clini-
cal ischemic events.10,11 A shift to dual pathway antithrombotic
management is also advocated in the 2018 updates of the CCS anti-
platelet and atrial fibrillation guidelines.16,17 The recently published
AUGUSTUS trial (apixaban), that also included medically managed
ACS patients, also supports the safety advantage of dual pathway
therapy over triple therapy.12 The ENTRUST-PCI AF trial (edoxaban)
furtherly reinforced the safety and anti-ischemic efficacy of dual path-
way regimens of dual pathway over triple therapy, with no significant
difference in ischemic events between the two groups.18
Interventional cardiologists at our center no longer appear to be
avoiding DES in AF patients when anticoagulation is indicated. Histor-
ically, bare-metal stents (BMS) had been preferred for many patients
requiring OAC because of the shorter DAPT duration required with
BMS.17,19 More recently, however, the recognition that shorter
courses of DAPT (3-6 months) with second generation DES are likely
safe,17,20-23 combined with evidence of a safety advantage for
NOAC-based antithrombotic regimens is likely largely responsible for
this observed change in stent choice. Additionally, recent studies
among patients at high risk for bleeding, including those requiring
OAC, have demonstrated the superior efficacy and safety of using
certain DES platforms compared to BMS when shorter courses of
DAPT are necessary.24,25 Avoidance of restenosis with the use of
DES may also help reduce the risk of bleeding complications by
avoiding repeat procedures in a typically fragile AF population.26
5 | LIMITATIONS
Certain limitations must be acknowledged given the retrospective
nature of this analysis. First, while the registry is prospective and
ongoing, data were abstracted from patients' medical records, giving
rise to the possibility of ascertainment bias. Secondly, there is the
potential for some “noise” around the ACS presentation variable due
to the likely inclusion of some cases of crescendo angina as “unstable.”
Nevertheless, we believe the impact of this variability to be minimal.
Furthermore, the type of presentation (ACS vs non-ACS) would not
affect the recommended antithrombotic therapy prescribed at dis-
charge according to the 2016 AF guidelines (though it would impact
the duration). Finally, as this study was conducted in a single tertiary
academic center, these results are not necessarily indicative of clinical
practice in community centers or other Canadian academic centers.
6 | CONCLUSION
While the impact of the availability of novel antithrombotic agents
without clinical guidelines lead to increased practice variability, the
combination of the 2016 CCS AF guidelines and landmark clinical tri-
als appears to have had a major impact on antithrombotic regimen
prescriptions for AF patients undergoing PCI at our center, with signif-
icantly higher rates of TATT and dual pathway regimen prescription in
the most recent cohort. Guideline adherence was high overall, but
room for improvement still exists, particularly in light of the most
recent guidelines updates.
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